Join to View Full Profile
2050 Kenny RdColumbus, OH 43221
Phone+1 614-293-4969
Fax+1 614-293-6111
Dr. Kostyk is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sandra Kostyk is a neurologist based in Columbus, OH, specializing in neurodegenerative disorders. She received her medical training from the University of Chicago, with a residency in neurology at Harvard-affiliated hospitals. Her expertise includes movement disorders, Huntington's disease, and Parkinson's disease, among others. Dr. Kostyk has published several peer-reviewed articles, notably on Huntington's disease, and is involved in clinical trials related to this condition. She has been recognized with several honors, including being named an Exceptional Women in Medicine in Neurology by Castle Connolly in 2020.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1986 - 1989
University of ChicagoInternship, Internal Medicine, 1985 - 1986
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1985
Certifications & Licensure
OH State Medical License 1998 - 2026
MA State Medical License 1989 - 2002
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Exceptional Women in Medicine (Neurology) Castle Connolly, 2020
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
Clinical Trials
- Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E) Start of enrollment: 2009 Sep 01
- Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease Start of enrollment: 2010 Apr 01
- Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort Start of enrollment: 2012 Jul 01
Publications & Presentations
PubMed
- 3 citationsPridopidine in early-stage manifest Huntington's disease: a phase 3 trial.Ralf Reilmann, Andrew Feigin, Anne E Rosser, Sandra K Kostyk, Carsten Saft
Nature Medicine. 2025-11-01 - 1 citationsImproving the Clinical Diagnostic Criteria for Genetically Confirmed Adult-Onset Huntington Disease: Considering Nonmotor Presentations.Ciaran M Considine, Clare M Eddy, Samuel A Frank, Sandra K Kostyk, Mayke Oosterloo
Neurology. Clinical Practice. 2025-04-01 - 2 citationsWhat Huntington's Disease Patients Say About Their Illness: An Online Direct-to-Participant Pilot Study.Karen E Anderson, Lakshmi Arbatti, Abhishek Hosamath, Andrew Feigin, Jody Goldstein
Journal of Huntington's Disease. 2024-01-01
Press Mentions
CIRM Funded Trial for Parkinson’s Treats First PatientSeptember 14th, 2020- Wexner Medical Center Performs First Gene Therapy Brain Infusion for Parkinson’s DiseaseSeptember 4th, 2020
The First Gene Therapy Clinical Trial in Huntington’s Disease Initiated by uniQureNovember 3rd, 2019
Grant Support
- FGF In The Visual SystemNational Eye Institute1991–1993
- FGF In The Visual SystemNational Eye Institute1989–1990
Professional Memberships
- Member
- Member
- Huntington Study GroupMember
- Parkinson Study GroupMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
